AV 0113

Drug Profile

AV 0113

Alternative Names: AV0113; Cancer vaccine - Activartis; Cancer vaccine - Trimed; Dendritic cell vaccine - Activartis; Trivax cancer vaccine

Latest Information Update: 12 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trimed Biotech
  • Developer Activartis Biotech
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes - Brain cancer

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Solid tumours
  • Clinical Phase Unknown Prostate cancer; Sarcoma
  • No development reported Renal cell carcinoma

Most Recent Events

  • 01 Oct 2015 Activartis Biotech completes a phase I trial in Solid tumours (In children, Late-stage disease) in Austria (Intralymphatic) (NCT02533895)
  • 13 Aug 2015 Phase-II development is ongoing for Glioblastoma in Austria
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Renal cell carcinoma (Combination therapy, Metastatic disease) in Czech Republic, Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top